Our results suggest that an effective treatment to slow or prevent early pathogenic events in sAD may involve attenuation of brain insulin resistance in AD, which highlights the therapeutic potential of future research on brain insulin resistance, including IGF-1 signaling as a novel therapeutic target for Alzheimer’s disease treatment. The gene discussed is INS; the disease is early-onset autosomal dominant Alzheimer disease.